GenVec, Naval Medical Research Center deal

GenVec signed a $3.5 million contract with the research center to support malaria development. GenVec will be responsible for producing its NMRC-M3V-Ad-PfCA malaria vaccine, which uses the company's adenovector delivery technology. The center will then use a clinical challenge model developed under the U.S. Military Malaria Vaccine Program (USMMVP) to assess the vaccine's safety and efficacy. GenVec retains rights to commercialize its adenovector delivery technology, which generates strong immune responses while avoiding vector-specific immunity. The parties could not be reached for details. ...